Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.

World Journal of Urology
Paul TorenYves Fradet

Abstract

The impact of sex hormones on cancer immunotherapy remains controversial. Androgens, via the androgen receptor (AR), may impact the success of immune checkpoint blockade. This study characterizes AR and programmed death ligand-1 (PD-L1) expression in bladder tumors with long clinical follow-up. AR and PD-L1 expression was analyzed using immunohistochemistry on 143 transurethral resection (TUR) and 203 radical cystectomy (RC) specimens. Descriptive statistics and survival analyses assessed the relationship of AR and PD-L1 staining with clinical outcomes of tumor recurrence, progression, and overall survival. AR expression was observed in a higher proportion of TUR than RC specimens (59% vs 35%, p < 0.001). High immune cell (IC) PD-L1 expression was associated with higher stage and grade. Patients with the combination of an absence of AR expression and the highest (> 10%) IC PD-L1 expression in TUR tumors had an increased risk of recurrence and progression. In RC specimens, the expression of AR increased the risk of local recurrence (adjusted hazard ratio (HR) 2.09, 95% CI 0.98-4.45), which was even higher among patients who also had IC PD-L1 expression (HR 4.16, 95% CI 1.28-13.52). For 28 paired metastatic lymph nodes among RC p...Continue Reading

References

Jul 2, 2004·Histopathology·A J BirtleP Munson
Apr 5, 2007·Journal of the National Cancer Institute·Hiroshi MiyamotoChawnshang Chang
Jan 6, 2015·Oncotarget·Koji IzumiHiroji Uemura
Nov 29, 2017·Molecular and Clinical Oncology·Jinbo ChenXiongbing Zu
May 8, 2018·The Journal of Urology·Ville J MäkeläTeemu J Murtola
May 21, 2018·The Lancet Oncology·Fabio ConfortiAron Goldhirsch
May 21, 2019·Journal of the National Cancer Institute·Fabio ConfortiAron Goldhirsch
Jun 14, 2019·Cancer Management and Research·Xiangli DingDelin Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
Alice DelafoyUlrike Schick
© 2021 Meta ULC. All rights reserved